Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Mainz Biomed NV MYNZ

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of... see more

Recent & Breaking News (NDAQ:MYNZ)

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

GlobeNewswire April 25, 2024

Mainz Biomed Reports Full Year 2023 Financial Results

GlobeNewswire April 9, 2024

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

GlobeNewswire March 19, 2024

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

GlobeNewswire March 18, 2024

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

GlobeNewswire March 12, 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

GlobeNewswire March 5, 2024

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

GlobeNewswire February 27, 2024

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

GlobeNewswire February 22, 2024

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

GlobeNewswire February 21, 2024

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

GlobeNewswire February 6, 2024

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

GlobeNewswire January 11, 2024

Mainz Biomed Provides Year-End Corporate Review 2023

GlobeNewswire January 9, 2024

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

GlobeNewswire December 19, 2023

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

GlobeNewswire December 12, 2023

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

GlobeNewswire December 5, 2023

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

GlobeNewswire November 29, 2023

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 20, 2023

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 16, 2023

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

GlobeNewswire November 15, 2023

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

GlobeNewswire November 13, 2023